Over the last decade, great progress has been made in developing new global health technologies that show potential to transform the deadliest diseases on earth. This progress has been delivered largely by Product Development Partnerships (PDPs), with critical support from the public, private and philanthropic sectors, which have filled the gap by developing new technologies to prevent, diagnose and treat diseases affecting the world’s most underserved populations.
Despite the urgent need for new tools, the recently released G-FINDER report reveals that overall global investment in the research and development (R&D) of such products has declined for the first time since 2007, when the tracking of such funding began. This decline is especially troubling given that there are more than 100 products in PDPs’ pipelines. In the case of tuberculosis, novel vaccines are undergoing testing in clinical trials and new treatments are in late-stage development, giving promise to the availability of new solutions in the near term.